Intravitreal Aflibercept in Neovascular Age-related Macular Degeneration (nAMD): an Observational Study Assessing Patient Relevant Outcomes, Real-world Treatment Pattern and Effectiveness
Phase of Trial: Phase IV
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms ANDROMEDA
- Sponsors Bayer
- 31 Oct 2019 Planned End Date changed from 30 Jun 2022 to 31 Mar 2023.
- 31 Oct 2019 Planned primary completion date changed from 31 Mar 2022 to 31 Dec 2022.
- 04 Feb 2019 Status changed from not yet recruiting to recruiting.